Last reviewed · How we verify
Mydriatics Agent
At a glance
| Generic name | Mydriatics Agent |
|---|---|
| Sponsor | RETINA-AI Health, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection
- Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution (PHASE1, PHASE2)
- Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
- Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images
- Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device
- Cycloplegic Refraction in Pediatric Patients With Esotropia (PHASE4)
- Mydriatic Drops After Combined Surgery (NA)
- Assessment of EyeArt Performance With Retinal Cameras
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mydriatics Agent CI brief — competitive landscape report
- Mydriatics Agent updates RSS · CI watch RSS
- RETINA-AI Health, Inc. portfolio CI